Aktienanalyse zu Coya Therapeutics Inc (COYA)COYACoya Therapeutics Inc

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Coya Therapeutics is currently not a good buy due to its low price and high volatility, despite a bullish analyst rating. The current price is $3.23, significantly below the analyst target of $12, indicating potential upside. However, the RSI is at 11.165, suggesting the stock is oversold, and the recent 5-day change is -18.23%, indicating a strong downward momentum. The main risk is the company's ongoing losses, with a net income loss of $7.2 million reported in Q1 2026, which raises concerns about its financial health.